Is not of reproductive potential, or is of reproductive potential and agrees to avoid becoming pregnant or impregnating a partner while receiving trial medication or within 6 months after the last dose of trial medication
Has chronic back pain of =3 months duration by history
Has physician-diagnosed active nr-axSpA with disease duration <= 5 years
• Inflammatory back pain
• Arthritis (physician-diagnosed)
• Enthesitis (heel) physician-diagnosed (spontaneous pain or tenderness at examination of the site of the insertion of the Achilles tendon or plantar fascia)
• Dactylitis (physician-diagnosed)
• Psoriasis (physician-diagnosed)
• History of physician-diagnosed inflammatory bowel disease (IBD)
• History of uveitis confirmed by an ophthalmologist
• Good response to nonsteroidal anti-inflammatory drugs (NSAID)
• Family history of SpA (presence of ankylosing spondylitis, psoriasis, acute uveitis, reactive arthritis, or IBD)
• Elevated CRP
• Human leukocyte antigen B27 (HLA-B27)+ gene
Has a HLA-B27+ gene and 2 or more of the SpA characteristics listed above
Has elevated CRP at Screening or evidence of active inflammation in the sacroiliac joints on MRI
Has an ASDAS >= 2.1 at Screening
Shows high disease activity at Screening and Baseline of both a Total Back Pain score of =4 and a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of >= 4
Has an acceptable history of NSAID use
Has no history of untreated latent or active tuberculosis (TB) prior to Screening
Has had no recent close contact with a person with active TB or, if there has been such contact, will undergo additional evaluations and receive appropriate treatment for latent TB
